

2023 Cancer Steering Committee Scientific Symposium

Day 1: Tuesday November 14, 2023

11:00 **Registration & Lunch**

12:00 **Opening Remarks**

12:45 **Session 1: Independent vs. Synergistic Activity of Drugs in Combination**

Moderator: Emmett Schmidt, Merck and Co; Inc

12:45 **Keynote: Drug Independence: Implications for Drug Discovery and Precision Medicine in Oncology**

Peter Sorger, Harvard Medical School

1:20 **Debate: Independent Action vs. Synergy**

Adam Palmer, UNC Chapel Hill

Michael A. Curran, The University of Texas MD Anderson Cancer Center / ImmunoGenesis Inc.

2:00 **Panel Discussion: When will precision medicine replace the “bet hedging” used in current combination cancer therapies?**

Geoff Oxnard, Loxo Oncology @ Lilly

Emmett Schmidt, Merck and Co; Inc

David Solit, Memorial Sloan Kettering Cancer Center

Baolin Zhang, U.S. Food & Drug Administration

2:45 **Coffee Break**

3:15 **Keynote: Novel Endpoint Development in Oncology**

Nicole Gormley, U.S. Food & Drug Administration

3:50 **Working Session 1: Digital and Computational Pathology**

Moderator: Brandon Gallas, U.S. Food & Drug Administration

3:50 **Digital and Computational Pathology Past, Present and Future**

J. Carl Barrett, University of North Carolina

4:05 **Introduction to the Pathology Innovation Collaborative Community (PICC): Challenges and Needs in Digital Pathology**

Joe Lennerz, MGH

4:15 **MedPerf: An open benchmarking platform for medical AI, enabling healthcare stakeholders to assess the performance of AI models in an efficient and human-supervised approach**

Alex Karargyris, MLCommons

4:30 **Collecting, curating, and sharing regulatory-ready data to assess the performance of pathologists and AI/ML models**

Brandon Gallas, U.S. Food & Drug Administration

4:45 **Coffee Break**

5:00 **Bridge of Trust – From Patient Care to Innovation**

Matthew O. Leavitt, LUMEA & DDx Foundation

5:15 **A Multi-Stakeholder Regulatory Science Initiative to Create a Sustainable Ecosystem for Data Driven Diagnostics**

Joe Lennerz, MGH

5:30 **Interactive Data Gathering: Attendee Polls**

5:45 **Panel Discussion**

Moderator: Joe Lennerz, MGH

Kim RM Blenman, Yale University

Brandon Gallas, U.S. Food & Drug Administration

Alexandra N. Kalof, University of Vermont Health Network

Laura Lasiter, AstraZeneca

J. Carl Barrett, University of North Carolina

Alex Karargyris, MLCcommons

Matthew O. Leavitt, LUMEA & DDx Foundation

6:15 **Reception**

Day 2: Wednesday November 15, 2023

8:00 **Registration & Breakfast**

9:00 **Opening Remarks**

9:15 **Session 2: Early Disease – Detection and Treatment**

Moderator: Gary Kelloff, National Cancer Institute, NIH

9:15 **Keynote: Rare Cancer Models for Developmental Therapeutics**

James H. Doroshow, National Cancer Institute, NIH

9:50 **Neoadjuvant Immunotherapy: Leveraging the Immune System to Treat Early-Stage Disease**

Bruce E. Johnson, Dana-Farber Cancer Institute

10:15 **Coffee Break**

10:30 **Panel Discussion**

Nicholas C. Dracopoli, Delfi Diagnostics

Robert Iannone, Jazz Pharmaceuticals

Jennifer Litton, The University of Texas MD Anderson Cancer Center

Elad Sharon, Dana-Farber Cancer Institute

11:30 **CSC Project Highlight: The Promise of Early Detection and Interception in Myeloma**

Irene Ghobrial, Dana-Farber Cancer Institute

12:00 **Lunch**

1:00 **Working Session 2: Liquid Biopsy – from Mutations to Gene Expression**

Moderator: Mickey Williams, Frederick National Laboratory for Cancer Research

1:00 **Keynote: ctDNA analysis as a tool for precision drug development**

Geoff Oxnard, Loxo Oncology @ Lilly

Liquid Biopsy Today

1:35 **Liquid Biopsies for Solid Tumor Drug Development: Regulatory Considerations**

Paz Vellanki, U.S. Food & Drug Administration

1:55 **Development of FNIH Quality Control Materials for Circulating Tumor DNA**

Chris Karlovich, Frederick National Laboratory for Cancer Research

2:15 **MRD in AML**

Christopher Hourigan, Intramural Program, NHLBI, NIH

Liquid Biopsy Tomorrow

2:35 **Exploring the potential of epigenomic liquid biopsies to impact cancer care**

Jacob Berchuck, Dana-Farber Cancer Institute, Harvard Medical School

2:55 **From Clinical Outcome to Clinical Assay: A Study of Blood-Based, 3D Genomic Biomarkers for the Checkpoint Inhibitor Response Test (CiRT)**

Alexandre Akoulitchev, Oxford BioDynamics

3:15 **Panel Discussion: Objectives for CSC Liquid Biopsy Project in Development**

Alexandre Akoulitchev, Oxford BioDynamics

Jacob Berchuck, Dana-Farber Cancer Institute, Harvard Medical School

Craig Cummings, Genentech

Zhiyong He, NIST

Christopher Hourigan, NHLBI

Chris Karlovich, Frederick National Laboratory for Cancer Research

Diana Merino Vega, AstraZeneca

Paz Vellanki, U.S. Food & Drug Administration

4:10 **Break-out Groups: How can the CSC translate development of liquid biopsy technologies into an impactful public-private partnership**

5:15 **Closing Remarks**